Morgan Stanley Maintains Overweight on Dyne Therapeutics, Raises Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz maintains an Overweight rating on Dyne Therapeutics (NASDAQ:DYN) and raises the price target from $48 to $52.
August 14, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley analyst Michael Ulz maintains an Overweight rating on Dyne Therapeutics and raises the price target from $48 to $52.
The Overweight rating and increased price target from a reputable analyst at Morgan Stanley is likely to boost investor confidence and positively impact the stock price of Dyne Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100